glp1ledger

How a GLP-1 Prescription Actually Happens: The Four Gates

Between wanting a GLP-1 and holding one there are four gates, and only one of them is about money. The label's own eligibility criteria, the contraindications that close the door outright, the payer's question and the supply channel — each read from the source that controls it.

Ronald R · Edited by Caroline S · Published 2026-09-20

Illustration: A stack of four blank, muted-colored medical forms on a wooden desk, lit by natural light.
Illustration

There is no single step between wanting a GLP-1 and having one. There are four, they are controlled by four different authorities, and only the last of them is about money.

This page reads each gate from the document that governs it: the label for who the drug is for and who it is forbidden to, the statute for who pays, and the manufacturers' own channels for where it comes from.

Gate one: the indication

The eligibility test is not a guideline sitting beside the label. It is the label's first sentence, and on all four weight-management products it is the same sentence.

indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition

That wording is identical on WEGOVY, ZEPBOUND, SAXENDA and FOUNDAYO, read 2026-09-20. SAXENDA and WEGOVY extend it to patients aged 12 and older with obesity; SAXENDA adds a body-weight floor of 60 kg for that group.

What the indication does not do is print a BMI number. The thresholds everyone quotes come from the trials, and SURMOUNT-5 states them in as many words: a BMI of 30 or above, or 27 or above with a previously diagnosed comorbidity — "hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease."

Two products reach past weight entirely. ZEPBOUND carries a separate indication to treat moderate to severe obstructive sleep apnoea in adults with obesity. WEGOVY carries one to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and a third, under accelerated approval, for noncirrhotic MASH with stage F2 to F3 fibrosis. These are different doors into the same molecules, and as gate three shows, they are the doors that decide who pays.

Gate two: the contraindications

Eligibility says who the drug is for. The contraindication says who it is not for, and it is the only gate on this page that nothing can open.

Every product in this class carries the same one, in a boxed warning at the top of the label:

contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

The labels also carry a limitation of use that catches more people than it first appears to: combining these products is not recommended. ZEPBOUND's label states that coadministration "with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended"; FOUNDAYO's says the same of "another GLP-1 receptor agonist." A person already on one of these drugs is, by the labels' own terms, not a candidate for a second.

Beyond the contraindications the labels list warnings rather than bars — pancreatitis, gallbladder disease, diabetic retinopathy in patients with diabetes, aspiration risk around procedures, pregnancy. Those are matters for a clinician to weigh, and the weighing is the consultation.

Gate three: who pays, and it turns on a word

The third gate is not a price. It is a sentence of federal law written in 1990, and it excludes these drugs by use rather than by name: programmes may exclude "Agents when used for anorexia, weight loss, or weight gain."

Because the exclusion attaches to the use, the same prescription for the same person at the same dose can sit inside or outside it depending on which approved indication it is written under. This is the mechanism, not a loophole, and it is the reason ZEPBOUND's sleep-apnoea indication and WEGOVY's cardiovascular indication carry commercial weight far beyond the number of patients they describe.

The full statutory reading, with the parallel Congress wrote for a different drug class, is on the insurance-coverage page. The named programmes — savings cards, the $50 Medicare Bridge — are on the cost page.

Gate four: the channel

Only after the first three does the question of where the product comes from arise, and by then most of the variation is in price rather than in access. The manufacturer-direct programmes, the pharmacy route, and what a telehealth membership adds on top of the drug are all dated and priced on the cost page; the provider-by-provider picture is on the cost of a Ro subscription and its siblings.

One thing is worth stating here rather than there, because it belongs to access and not to price: there is no over-the-counter GLP-1. Nothing sold without a prescription — no patch, capsule, probiotic, tea or "booster" — is an approved GLP-1 medicine, whatever the packaging says. That market is documented on the over-the-counter page, the patch page and the brand table.

The compounded route is a different question again, and a narrower one than it is usually described as: what the compounding statute actually says.

What the prescriber is doing at each gate

Collected in one place, the labels put these tasks on whoever writes the prescription, whatever the format of the visit:

  1. Establish that the person meets the indication — obesity, or overweight with a weight-related condition, or one of the specific non-weight indications.
  2. Screen for the boxed-warning contraindication and for prior severe hypersensitivity.
  3. Check that no other GLP-1 receptor agonist is in use.
  4. Select a starting dose and manage the escalation schedule, which on most of these products takes four to five months to reach the dose the trials measured — see the titration schedules.
  5. Counsel on the label's specified risks, which section 17 of every one of these documents sets out at length.

What this page is not

It is not advice about obtaining a prescription, an assessment of whether any reader qualifies, or a comparison of providers. It is a description of the gates and of the documents that define them. Whether a GLP-1 is appropriate for a particular person is a clinical decision, and the labels quoted here are written for the clinician making it.

Sources

  • WEGOVY label (semaglutide), DailyMed SPL, version dated 2026-06-30, read 2026-09-20.
  • ZEPBOUND label (tirzepatide), DailyMed SPL, version dated 2026-09-02, read 2026-09-20.
  • SAXENDA label (liraglutide), DailyMed SPL, version dated 2026-06-15, read 2026-09-20.
  • FOUNDAYO label (orforglipron), DailyMed SPL, version dated 2026-08-13, read 2026-09-20.
  • SURMOUNT-5, NCT05822830, eligibility criteria, ClinicalTrials.gov, read 2026-09-20.
  • 42 U.S.C. 1396r-8(d)(2)(A), quoted as read for the coverage page on 2026-09-11.

Frequently asked questions

Who is eligible for a GLP-1 for weight loss?

The indication on all four weight-management labels is the same: adults with obesity, or adults with overweight who also have at least one weight-related comorbid condition. The trials behind them enrolled at a BMI of 30 or above, or 27 or above with a condition such as hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. WEGOVY and SAXENDA also carry paediatric indications from age 12. Whether a particular person fits is a clinical judgement made by a prescriber with the record in front of them.

Do you need a prescription for a GLP-1?

Yes, for every one of them, without exception. None of these products is available over the counter in the United States, and nothing sold without a prescription as a patch, capsule, tea, probiotic or GLP-1 'booster' is an approved GLP-1 medicine. That is covered in full on the over-the-counter page.

What stops someone from being prescribed a GLP-1?

The hardest stop is a contraindication rather than an eligibility rule. Every label in the class is contraindicated in a person with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2, and this sits in a boxed warning. Prior severe hypersensitivity to the product is a second. Beyond the contraindications, the labels list situations calling for caution rather than exclusion — a history of pancreatitis, severe gastrointestinal disease, diabetic retinopathy, pregnancy — and those are clinical conversations, not automatic refusals.

Does a telehealth visit count as getting a prescription?

A prescription from a licensed clinician is a prescription however the consultation happened. What differs between channels is what the consultation covers, what records the clinician sees, and what happens afterwards if something goes wrong. The labels put several requirements on the prescriber — screening for the boxed-warning contraindications, checking for concurrent GLP-1 use, managing escalation and tolerability — and none of them is waived by the format of the visit.

Can you be prescribed a GLP-1 if you do not have diabetes?

Yes. WEGOVY, ZEPBOUND, SAXENDA and FOUNDAYO are all approved for weight management in people without diabetes, and the pivotal trials for those indications excluded patients with type 2 diabetes. The diabetes products — OZEMPIC, MOUNJARO, TRULICITY, VICTOZA — are a separate set of labels for a separate indication, and prescribing one of those for weight loss is prescribing outside its approved indication.

Why does the same drug get covered for one person and not another?

Because the exclusion in federal law attaches to the use, not to the drug. Programmes may exclude 'agents when used for anorexia, weight loss, or weight gain', so the identical molecule at the identical dose can be inside or outside the exclusion depending on which approved indication the prescription is written under — which is why ZEPBOUND's sleep-apnoea indication and WEGOVY's cardiovascular indication matter so much more than they look.